tetano
Editor, Senior Moderator
Nat Rev Immunol
. 2023 Mar 21;1-2.
doi: 10.1038/s41577-023-00868-8. Online ahead of print.
We need to keep an eye on avian influenza
Florian Krammer[SUP] 1 2 3 [/SUP], Stacey Schultz-Cherry[SUP] 4 [/SUP]
Affiliations
Abstract
H5N1 avian influenza viruses of the A/goose/Guangdong/1/96 lineage have been circulating in wild birds for many years, have inflicted significant economic losses on the poultry industry and have caused zoonotic infections since 1997. However, the recent spread of avian H5N1 virus to the Americas and its detection in mammals have raised concerns about its pandemic potential.
Conflict of interest statement
F.K. has been consulting for Curevac, Seqirus and Merck and is currently consulting for Pfizer, Third Rock Ventures, Avimex and GSK. He is named on several patents regarding influenza virus and SARS-CoV-2 vaccines, influenza virus therapeutics and SARS-CoV-2 serological tests. Some of these technologies have been licensed to commercial entities and F.K. is receiving royalties from these entities. F.K. is also an advisory board member of Castlevax, a spin-off company formed by the Icahn School of Medicine at Mount Sinai to develop SARS-CoV-2 vaccines. The Krammer laboratory has received funding for research projects from Pfizer, GSK and Dynavax and three of F.K.’s mentees have recently joined Moderna. S.S.-C. declares no competing interests.
. 2023 Mar 21;1-2.
doi: 10.1038/s41577-023-00868-8. Online ahead of print.
We need to keep an eye on avian influenza
Florian Krammer[SUP] 1 2 3 [/SUP], Stacey Schultz-Cherry[SUP] 4 [/SUP]
Affiliations
- PMID: 36944755
- PMCID: PMC10028763
- DOI: 10.1038/s41577-023-00868-8
Abstract
H5N1 avian influenza viruses of the A/goose/Guangdong/1/96 lineage have been circulating in wild birds for many years, have inflicted significant economic losses on the poultry industry and have caused zoonotic infections since 1997. However, the recent spread of avian H5N1 virus to the Americas and its detection in mammals have raised concerns about its pandemic potential.
Conflict of interest statement
F.K. has been consulting for Curevac, Seqirus and Merck and is currently consulting for Pfizer, Third Rock Ventures, Avimex and GSK. He is named on several patents regarding influenza virus and SARS-CoV-2 vaccines, influenza virus therapeutics and SARS-CoV-2 serological tests. Some of these technologies have been licensed to commercial entities and F.K. is receiving royalties from these entities. F.K. is also an advisory board member of Castlevax, a spin-off company formed by the Icahn School of Medicine at Mount Sinai to develop SARS-CoV-2 vaccines. The Krammer laboratory has received funding for research projects from Pfizer, GSK and Dynavax and three of F.K.’s mentees have recently joined Moderna. S.S.-C. declares no competing interests.